These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 12359687)

  • 1. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
    Stein MB; Kline NA; Matloff JL
    Am J Psychiatry; 2002 Oct; 159(10):1777-9. PubMed ID: 12359687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel augmentation strategy for treating resistant major depression.
    Shelton RC; Tollefson GD; Tohen M; Stahl S; Gannon KS; Jacobs TG; Buras WR; Bymaster FP; Zhang W; Spencer KA; Feldman PD; Meltzer HY
    Am J Psychiatry; 2001 Jan; 158(1):131-4. PubMed ID: 11136647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.
    Marangell LB; Johnson CR; Kertz B; Zboyan HA; Martinez JM
    J Clin Psychiatry; 2002 May; 63(5):391-5. PubMed ID: 12019662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
    Weimer E; Braus DF; Cavus I; Thome J
    Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
    Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
    J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
    J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
    Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy.
    Hamner MB; Hernandez-Tejada MA; Zuschlag ZD; Agbor-Tabi D; Huber M; Wang Z
    J Clin Psychopharmacol; 2019; 39(2):153-157. PubMed ID: 30640209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.
    Jakovljević M; Sagud M; Mihaljević-Peles A
    Acta Psychiatr Scand; 2003 May; 107(5):394-6; discussion 396. PubMed ID: 12752037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
    Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
    J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
    Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
    J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
    Tohen M; Case M; Trivedi MH; Thase ME; Burke SJ; Durell TM
    J Clin Psychiatry; 2010 Apr; 71(4):451-62. PubMed ID: 20361905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
    Pollack MH; Simon NM; Zalta AK; Worthington JJ; Hoge EA; Mick E; Kinrys G; Oppenheimer J
    Biol Psychiatry; 2006 Feb; 59(3):211-5. PubMed ID: 16139813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.